Laura Okpala
Executive Director & Head of Reimbursement Policy & Government Affairs Gilead Sciences
At Gilead Sciences, Ms. Okpala leads the US reimbursement policy team focused on driving access to innovative medicines across Gilead’s oncology and virology portfolio, including reimbursement strategies for Kite Pharma, a leader in the development of novel CAR T therapies.
